<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CABERGOLINE- cabergoline tablet </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d9e8ad46-f333-41a6-8631-c7353c4b462d"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cabergoline tablets contain cabergoline, a dopamine receptor agonist. The chemical name for cabergoline is 1-[(6-Allylergolin-8ß-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea. Its molecular formula is C<span class="Sub">26</span>H<span class="Sub">37</span>N<span class="Sub">5</span>O<span class="Sub">2</span>, and its molecular weight is 451.6. The structural formula is as follows:</p>
<div class="Figure">
<a name="id247"></a><img alt="Cabergoline Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0e2a2cb6-e453-4060-95f4-a8ce4ccecc10&amp;name=e068ef51-a8cb-428a-9ab0-89d482ad7527-01.jpg">
</div>
<p>Cabergoline, USP is a white or almost white crystalline powder soluble in ethyl alcohol, chloroform, and N, N-dimethylformamide (DMF); slightly soluble in 0.1N hydrochloric acid; very slightly soluble in n-hexane; and insoluble in water.</p>
<p> Each tablet, for oral administration, contains 0.5 mg of cabergoline. Inactive ingredients consist of anhydrous lactose, leucine and magnesium stearate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_8326bfc1-ea14-425d-b32d-9654c343c30c"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_6e37b44e-d3ee-4bf4-a784-6ba780634e74"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">The secretion of prolactin by the anterior pituitary is mainly under hypothalamic inhibitory control, likely exerted through release of dopamine by tuberoinfundibular neurons. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D<span class="Sub">2</span> receptors. Results of <span class="Italics">in vitro </span>studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. Cabergoline decreased serum prolactin levels in reserpinized rats. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D<span class="Sub">1</span>, α<span class="Sub">1</span>- and α<span class="Sub">2</span>-adrenergic, and 5-HT<span class="Sub">1</span>- and 5-HT<span class="Sub">2</span>-serotonin receptors.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_9a9d2b4e-831a-4022-b2a7-2c7cc3fb4939"></a><a name="section-2.2"></a><p></p>
<h2>Clinical Studies</h2>
<p class="First">The prolactin-lowering efficacy of cabergoline was demonstrated in hyperprolactinemic women in two randomized, double-blind, comparative studies, one with placebo and the other with bromocriptine. In the placebo-controlled study (placebo n = 20; cabergoline n = 168), cabergoline produced a dose related decrease in serum prolactin levels with prolactin normalized after 4 weeks of treatment in 29%, 76%, 74% and 95% of the patients receiving 0.125 mg, 0.5 mg, 0.75 mg, and 1 mg twice weekly, respectively.</p>
<p> In the 8-week, double-blind period of the comparative trial with bromocriptine (cabergoline n = 223; bromocriptine n = 236 in the intent-to-treat analysis), prolactin was normalized in 77% of the patients treated with cabergoline at 0.5 mg twice weekly compared with 59% of those treated with bromocriptine at 2.5 mg twice daily. Restoration of menses occurred in 77% of the women treated with cabergoline, compared with 70% of those treated with bromocriptine. Among patients with <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, this symptom disappeared in 73% of those treated with cabergoline compared with 56% of those treated with bromocriptine.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_bc139440-fa3f-4fa4-bc9f-715f6e743234"></a><a name="section-2.3"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0dd2f4a6-80f5-4f35-ab67-c71dc0c07d41"></a><a name="section-2.3.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Following single oral doses of 0.5 mg to 1.5 mg given to 12 healthy adult volunteers, mean peak plasma levels of 30 to 70 picograms (pg)/mL of cabergoline were observed within 2 to 3 hours. Over the 0.5 mg to 7 mg dose range, cabergoline plasma levels appeared to be dose proportional in 12 healthy adult volunteers and nine adult parkinsonian patients. A repeat-dose study in 12 healthy volunteers suggests that steady-state levels following a once-weekly dosing schedule are expected to be 2-fold to 3-fold higher than after a single dose. The absolute bioavailability of cabergoline is unknown. A significant fraction of the administered dose undergoes a first-pass effect. The elimination half-life of cabergoline estimated from urinary data of 12 healthy subjects ranged between 63 to 69 hours. The prolonged prolactin-lowering effect of cabergoline may be related to its slow elimination and long half-life.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8f0d7d3a-50e9-42e4-b694-a129361eebd2"></a><a name="section-2.3.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">In animals, based on total radioactivity, cabergoline (and/or its metabolites) has shown extensive tissue distribution. Radioactivity in the pituitary exceeded that in plasma by &gt; 100-fold and was eliminated with a half-life of approximately 60 hours. This finding is consistent with the long-lasting prolactin-lowering effect of the drug. Whole body autoradiography studies in pregnant rats showed no fetal uptake but high levels in the uterine wall. Significant radioactivity (parent plus metabolites) detected in the milk of lactating rats suggests a potential for exposure to nursing infants. The drug is extensively distributed throughout the body. Cabergoline is moderately bound (40% to 42%) to human plasma proteins in a concentration-independent manner. Concomitant dosing of highly protein bound drugs is unlikely to affect its disposition.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_95e43570-454e-497e-8f12-95b66e2fec7e"></a><a name="section-2.3.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">In both animals and humans, cabergoline is extensively metabolized, predominately via hydrolysis of the acylurea bond or the urea moiety. Cytochrome P-450 mediated metabolism appears to be minimal. Cabergoline does not cause enzyme induction and/or inhibition in the rat. Hydrolysis of the acylurea or urea moiety abolishes the prolactin-lowering effect of cabergoline, and major metabolites identified thus far do not contribute to the therapeutic effect.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c5b69c20-c750-4a7d-a12b-2ef1668ea0f8"></a><a name="section-2.3.4"></a><p></p>
<h3>Excretion</h3>
<p class="First">After oral dosing of radioactive cabergoline to five healthy volunteers, approximately 22% and 60% of the dose was excreted within 20 days in the urine and feces, respectively. Less than 4% of the dose was excreted unchanged in the urine. Nonrenal and renal clearances for cabergoline are about 3.2 L/min and 0.08 L/min, respectively. Urinary excretion in hyperprolactinemic patients was similar.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b6b4f4f7-d848-4cd9-9a89-3e350048add0"></a><a name="section-2.4"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_38bc0e2b-79f8-456b-af6f-c964c379c85c"></a><a name="section-2.4.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h3>
<p class="First">The pharmacokinetics of cabergoline were not altered in 12 patients with moderate to severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> as assessed by creatinine clearance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1d14a3ff-a287-4882-9760-e3ab334b6ef0"></a><a name="section-2.4.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h3>
<p class="First">In 12 patients with mild to moderate hepatic dysfunction (Child-Pugh score ≤ 10), no effect on mean cabergoline C<span class="Sub">max</span> or area under the plasma concentration curve (AUC) was observed. However, patients with severe insufficiency (Child-Pugh score &gt; 10) show a substantial increase in the mean cabergoline C<span class="Sub">max</span> and AUC, and thus necessitate caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_843d48b9-ea77-42af-9c2e-328ec985a536"></a><a name="section-2.4.3"></a><p></p>
<h3>Elderly</h3>
<p class="First">Effect of age on the pharmacokinetics of cabergoline has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b7b6306c-1673-4fc1-82da-a1f7fd173975"></a><a name="section-2.5"></a><p></p>
<h2>Food-Drug Interaction</h2>
<p class="First">In 12 healthy adult volunteers, food did not alter cabergoline kinetics.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_46c74376-1ed2-4c2d-a047-85afa5ea360e"></a><a name="section-2.6"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Dose response with inhibition of plasma prolactin, onset of maximal effect, and duration of effect has been documented following single cabergoline doses to healthy volunteers (0.05 mg to 1.5 mg) and hyperprolactinemic patients (0.3 mg to 1 mg). In volunteers, prolactin inhibition was evident at doses &gt; 0.2 mg, while doses ≥ 0.5 mg caused maximal suppression in most subjects. Higher doses produce prolactin suppression in a greater proportion of subjects and with an earlier onset and longer duration of action. In 12 healthy volunteers, 0.5 mg, 1 mg and 1.5 mg doses resulted in complete prolactin inhibition, with a maximum effect within 3 hours in 92% to 100% of subjects after the 1 mg and 1.5 mg doses compared with 50% of subjects after the 0.5 mg dose.</p>
<p> In hyperprolactinemic patients (n = 51), the maximal prolactin decrease after a 0.6 mg single dose of cabergoline was comparable to 2.5 mg bromocriptine; however, the duration of effect was markedly longer (14 days vs. 24 hours). The time to maximal effect was shorter for bromocriptine than cabergoline (6 hours vs. 48 hours).</p>
<p> In 72 healthy volunteers, single or multiple doses (up to 2 mg) of cabergoline resulted in selective inhibition of prolactin with no apparent effect on other anterior pituitary hormones (GH, FSH, LH, ACTH, and TSH) or cortisol.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_4e9a0253-9026-4fbd-b810-5f670092ce84"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_1a592b74-aba5-491a-8e02-e3204ba164d6"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Cabergoline tablets are contraindicated in patients with:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> or known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ergot derivatives.</dd>
<dt>•</dt>
<dd>History of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis. (See <a href="#i4i_warnings_id_58966e35-1adc-4a10-abe1-1886674e70c5">WARNINGS</a><span class="Bold">.</span>)</dd>
<dt>•</dt>
<dd>History of pulmonary, pericardial, or retroperitoneal fibrotic disorders. (See <a href="#i4i_warnings_id_58966e35-1adc-4a10-abe1-1886674e70c5">WARNINGS</a><span class="Bold">.</span>)</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_58966e35-1adc-4a10-abe1-1886674e70c5"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_61693f13-b54a-40c5-a556-d4225eb13ab3"></a><a name="section-5.1"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Dopamine agonists in general should not be used in patients with pregnancy-induced <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, for example, preeclampsia, <span class="product-label-link" type="condition" conceptid="443700" conceptname="Eclampsia">eclampsia</span>, and post partum <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, unless the potential benefit is judged to outweigh the possible risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1abbf1ae-a7c7-4d37-a6d5-e8fe91009935"></a><a name="section-5.2"></a><p></p>
<h2>Fibrotic Complications</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_775a3e90-bec4-4b32-874c-5f087afdf495"></a><a name="section-5.2.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Cardiac Valvulopathy</span></h3>
<p class="First">All patients should undergo a cardiovascular evaluation, including echocardiogram to assess the potential presence of valvular disease. If valvular disease is detected, the patient should not be treated with cabergoline (see <a href="#i4i_contraindications_id_1a592b74-aba5-491a-8e02-e3204ba164d6">CONTRAINDICATIONS</a>). Post-marketing cases of <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">cardiac valvulopathy</span> have been reported in patients receiving cabergoline. These cases have generally occurred during administration of high doses of cabergoline (&gt; 2 mg/day) for the treatment of Parkinson’s disease. Cases of <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">cardiac valvulopathy</span> have also been reported in patients receiving lower doses of cabergoline for the treatment of hyperprolactinemic disorders.</p>
<p> A multi-country, retrospective cohort study using general practice records and record linkage systems in the U.K., Italy and the Netherlands was conducted to assess the association between new use of dopamine agonists including cabergoline (n = 27,812) for Parkinson’s disease and <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span> and cardiac valvular <span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">regurgitation</span> (CVR), other fibroses, and other cardiopulmonary events over a maximum of 12 years of follow up. In this study, the use of cabergoline among persons with Parkinson's disease was associated with an increased risk of CVR when compared to non-ergot-derived dopamine agonists (DAs) and levodopa [Incidence Rate (IR) per 10,000 person years of 68.1 (95% confidence interval (CI): 37.2 to 115.3) for cabergoline vs. 10 (95% CI: 5.2 to 19.4) for non-ergot DAs and 11.3 (95% CI: 7.2 to 17) for levodopa]. In the study analysis confined to persons with dopamine agonist-treated <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span> (n = 8,386), when compared to non-use (n = 15,147), persons exposed to cabergoline did not have an elevated risk of CVR. The findings with respect to the risk of CVR associated with cabergoline treatment for persons with Parkinson’s disease (increased risk) and those with <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span> (no increased risk) are consistent with the findings in other published studies. </p>
<p> Physicians should use the lowest effective dose of cabergoline for the treatment of hyperprolactinemic disorders and should periodically reassess the need for continuing therapy with cabergoline. Following treatment initiation, clinical and diagnostic monitoring (for example, chest x-ray, CT scan and cardiac echocardiogram) should be conducted to assess the risk of <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">cardiac valvulopathy</span>. The recommended frequency of routine echocardiographic monitoring is every 6 to 12 months or as clinically indicated with the presence of signs and symptoms such as <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, new <span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">cardiac murmur</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. </p>
<p> Cabergoline should be discontinued if an echocardiogram reveals new valvular <span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">regurgitation</span>, valvular restriction or valve leaflet thickening. </p>
<p> Cabergoline should be used with caution in patients exposed to other medications associated with valvulopathy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b200c0f6-ba3a-4398-a075-56adb3fea275"></a><a name="section-5.2.2"></a><p></p>
<h3>Extracardiac Fibrotic Reactions</h3>
<p class="First">Post-marketing cases of pleural, pericardial, and <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span> have been reported following administration of cabergoline. Some reports were in patients previously treated with other ergotinic dopamine agonists. Cabergoline should not be used in patients with a history of cardiac or extracardiac fibrotic disorders. </p>
<p> Fibrotic disorders can have an insidious onset and patients should be monitored for manifestations of progressive <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>. Therefore, during treatment, attention should be paid to the signs and symptoms of: </p>
<dl>
<dt>•</dt>
<dd>Pleuro-pulmonary disease such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, persistent <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>. </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal insufficiency</span> or ureteral/abdominal vascular obstruction that may occur with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the loin/flank and lower limb <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> as well as any possible <span class="product-label-link" type="condition" conceptid="192438" conceptname="Abdominal mass">abdominal masses</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> that may indicate <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span>. </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac failure</span>: Cases of valvular and <span class="product-label-link" type="condition" conceptid="4108230" conceptname="Fibrosis of pericardium">pericardial fibrosis</span> have often manifested as <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. Therefore, valvular <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> (and <span class="product-label-link" type="condition" conceptid="312334" conceptname="Constrictive pericarditis">constrictive pericarditis</span>) should be excluded if such symptoms occur. </dd>
</dl>
<p> Clinical and diagnostic monitoring such as <span class="product-label-link" type="condition" conceptid="434481" conceptname="Erythrocyte sedimentation rate - finding">erythrocyte sedimentation rate</span>, chest-x ray, serum creatinine measurements, and other investigations should be considered at baseline and as necessary while patients are treated with cabergoline. </p>
<p> Following diagnosis of <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> or <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, the discontinuance of cabergoline was reported to result in improvement of signs and symptoms. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_7df16457-d68a-4aee-8a42-5f03cb770166"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_881fb25c-2d4e-422c-97c8-9945e11be412"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Initial doses higher than 1 mg may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>. Care should be exercised when administering cabergoline with other medications known to lower blood pressure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3407688b-f270-4bf3-ab92-5dbc83dbdf6c"></a><a name="section-6.2"></a><p></p>
<h2>Postpartum Lactation Inhibition or Suppression</h2>
<p class="First">Cabergoline is not indicated for the inhibition or suppression of physiologic lactation. Use of bromocriptine, another dopamine agonist for this purpose, has been associated with cases of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c84473d-9279-4e4f-8381-89967a81f9ad"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Since cabergoline is extensively metabolized by the liver, caution should be used, and careful monitoring exercised, when administering cabergoline to patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4f68ef1b-8e37-45b4-b92b-5411681ed022"></a><a name="section-6.4"></a><p></p>
<h2>Psychiatric</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="436959" conceptname="Compulsive gambling">Pathological gambling</span>, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">increased libido</span>, and <span class="product-label-link" type="condition" conceptid="4032473" conceptname="Nymphomania">hypersexuality</span> have been reported in patients treated with dopamine agonists including cabergoline. This has been generally reversible upon reduction of the dose or treatment discontinuation (see <a href="#i4i_section_id_9b1b05f3-caab-46ab-811d-75477f40f58c">Post-Marketing Surveillance Data</a>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_7150d76a-3516-4886-85d3-975a66c434df"></a><a name="section-6.5"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be instructed to notify their physician if they suspect they are pregnant, become pregnant, or intend to become pregnant during therapy. A pregnancy test should be done if there is any suspicion of pregnancy and continuation of treatment should be discussed with their physician.</p>
<p> Patients should notify their physician if they develop <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, persistent <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, difficulty with breathing when lying down, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in their extremities.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_6bb3e0e7-c0b4-46c8-b6c3-740810c90ae5"></a><a name="section-6.6"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Cabergoline should not be administered concurrently with D<span class="Sub">2</span>-antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_9ba79e8b-2725-4105-a9fa-77a2e4b8530d"></a><a name="section-6.7"></a><p></p>
<h2>Carcinogenesis, Mutagenesis and Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies were conducted in mice and rats with cabergoline given by gavage at doses up to 0.98 mg/kg/day and 0.32 mg/kg/day, respectively. These doses are 7 times and 4 times the maximum recommended human dose calculated on a body surface area basis using total mg/m<span class="Sup">2</span>/week in rodents and mg/m<span class="Sup">2</span>/week for a 50 kg human.</p>
<p> There was a slight increase in the incidence of cervical and <span class="product-label-link" type="condition" conceptid="197236" conceptname="Uterine leiomyoma">uterine leiomyomas</span> and uterine leiomyosarcomas in mice. In rats, there was a slight increase in <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span> of the cervix and uterus and interstitial cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>. The occurrence of tumors in female rodents may be related to the prolonged suppression of prolactin secretion because prolactin is needed in rodents for the maintenance of the corpus luteum. In the absence of prolactin, the estrogen/progesterone ratio is increased, thereby increasing the risk for uterine tumors. In male rodents, the decrease in serum prolactin levels was associated with an increase in serum luteinizing hormone, which is thought to be a compensatory effect to maintain testicular steroid synthesis. Since these hormonal mechanisms are thought to be species-specific, the relevance of these tumors to humans is not known.</p>
<p> The mutagenic potential of cabergoline was evaluated and found to be negative in a battery of <span class="Italics">in vitro </span>tests. These tests included the bacterial mutation (Ames) test with <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span>, the gene mutation assay with <span class="Italics">Schizosaccharomyces pombe P<span class="Sub">1 </span></span>and V79 Chinese hamster cells, DNA damage and repair in <span class="Italics">Saccharomyces cerevisiae D<span class="Sub">4</span></span>, and chromosomal aberrations in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. Cabergoline was also negative in the bone marrow micronucleus test in the mouse.</p>
<p> In female rats, a daily dose of 0.003 mg/kg for 2 weeks prior to mating and throughout the mating period inhibited conception. This dose represents approximately 1/28 the maximum recommended human dose calculated on a body surface area basis using total mg/m<span class="Sup">2</span>/week in rats and mg/m<span class="Sup">2</span>/week for a 50 kg human.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_f1dc604b-f740-4847-b2b6-31332ba6d4a1"></a><a name="section-6.8"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_70722a0c-a828-4351-a011-09be2d03b42c"></a><a name="section-6.8.1"></a><p></p>
<h3>Teratogenic Effects. Pregnancy Category B</h3>
<p class="First">Reproduction studies have been performed with cabergoline in mice, rats, and rabbits administered by gavage.</p>
<p> (Multiples of the maximum recommended human dose in this section are calculated on a body surface area basis using total mg/m<span class="Sup">2</span>/week for animals and mg/m<span class="Sup">2</span>/week for a 50 kg human.) </p>
<p> There were maternotoxic effects but no teratogenic effects in mice given cabergoline at doses up to 8 mg/kg/day (approximately 55 times the maximum recommended human dose) during the period of organogenesis.</p>
<p> A dose of 0.012 mg/kg/day (approximately 1/7 the maximum recommended human dose) during the period of organogenesis in rats caused an increase in post-implantation embryofetal losses. These losses could be due to the prolactin inhibitory properties of cabergoline in rats. At daily doses of 0.5 mg/kg/day (approximately 19 times the maximum recommended human dose) during the period of organogenesis in the rabbit, cabergoline caused maternotoxicity characterized by a loss of body weight and decreased food consumption. Doses of 4 mg/kg/day (approximately 150 times the maximum recommended human dose) during the period of organogenesis in the rabbit caused an increased occurrence of various malformations. However, in another study in rabbits, no treatment-related malformations or embryofetotoxicity were observed at doses up to 8 mg/kg/day (approximately 300 times the maximum recommended human dose).</p>
<p> In rats, doses higher than 0.003 mg/kg/day (approximately 1/28 the maximum recommended human dose) from 6 days before parturition and throughout the lactation period inhibited growth and caused <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of offspring due to decreased milk secretion. </p>
<p>There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_b0a42b3c-193c-4586-97c1-2a2ede2a4afe"></a><a name="section-6.9"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from cabergoline, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Use of cabergoline for the inhibition or suppression of physiologic lactation is not recommended (see <a href="#i4i_precautions_id_7df16457-d68a-4aee-8a42-5f03cb770166">PRECAUTIONS</a>).</p>
<p> The prolactin-lowering action of cabergoline suggests that it will interfere with lactation. Due to this interference with lactation, cabergoline should not be given to women postpartum who are breast-feeding or who are planning to breast-feed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_209a0fa6-6480-4920-ac71-132a65c49727"></a><a name="section-6.10"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of cabergoline in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_33252d56-4aa1-4cd8-99bd-5be8f9c1da4e"></a><a name="section-6.11"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of cabergoline did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_e31fe024-7272-4bb7-acde-2d1e00acfc30"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The safety of cabergoline tablets has been evaluated in more than 900 patients with hyperprolactinemic disorders. Most adverse events were mild or moderate in severity.</p>
<p> In a 4-week, double-blind, placebo-controlled study, treatment consisted of placebo or cabergoline at fixed doses of 0.125 mg, 0.5 mg, 0.75 mg, or 1 mg twice weekly. Doses were halved during the first week. Since a possible dose related effect was observed for <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> only, the four cabergoline treatment groups have been combined. The incidence of the most common adverse events during the placebo-controlled study is presented in the following table.</p>
<a name="_Refid_add383b7-d40c-4b14-b1d4-56e93d829"></a><table>
<caption><span>Incidence of Reported Adverse Events During the 4-Week, Double-Blind, Placebo-Controlled Trial</span></caption>
<col width="42%">
<col width="34%">
<col width="18%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Reported at ≥ 1% for cabergoline</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Event</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Cabergoline ( n = 168)</span></p>
<p><span class="Bold">0.125 mg to 1 mg 2 times a week</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Placebo (n = 20)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Number (percent)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Gastrointestinal</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">45 (27)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4 (20)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">16 (10)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1 (5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Central and Peripheral Nervous System</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">43 (26)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (25)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">25 (15)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1 (5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Body as a Whole</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">15 (9)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (10)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">12 (7)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flashes</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1 (5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Psychiatric</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1 (5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (3)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1 (5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Autonomic Nervous System</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6 (4)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Reproductive – Female</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Vision </span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>In the 8-week, double-blind period of the comparative trial with bromocriptine, cabergoline (at a dose of 0.5 mg twice weekly) was discontinued because of an adverse event in 4 of 221 patients (2%) while bromocriptine (at a dose of 2.5 mg 2 times a day) was discontinued in 14 of 231 patients (6%). The most common reasons for discontinuation from cabergoline were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (three, two, and two patients, respectively); the most common reasons for discontinuation from bromocriptine were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> (ten, three, three, and three patients, respectively). The incidence of the most common adverse events during the double-blind portion of the comparative trial with bromocriptine is presented in the following table.</p>
<a name="_Refid_d72f827b-a42e-4b1d-bcfd-f9e243af2"></a><table>
<caption><span>Incidence of Reported Adverse Events During the 8-Week, Double-Blind Period of the Comparative Trial With Bromocriptine</span></caption>
<col width="42%">
<col width="14%">
<col width="17%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Reported at ≥ 1% for cabergoline</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Event</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Cabergoline</span></p>
<p><span class="Bold">(n = 221)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Bromocriptine</span></p>
<p><span class="Bold">(n = 231)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Number (percent)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Gastrointestinal</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">63 (29)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">100 (43)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">15 (7)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">21 (9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">12 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">19 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">16 (7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9 (4)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">16 (7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">7 (3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">Throat irritation</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">Toothache</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Central and Peripheral Nervous System</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">58 (26)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">62 (27)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">38 (17)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">42 (18)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9 (4)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">10 (4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6 (3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Body as a Whole</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">13 (6)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">15 (6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">10 (5)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">18 (8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4177665" conceptname="Periorbital edema">Periorbital edema</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Psychiatric</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">7 (3)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Impaired concentration</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Cardiovascular</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flashes</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6 (3)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4 (2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">Dependent edema</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Reproductive – Female</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8 (3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Skin and Appendages</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Musculoskeletal</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4 (2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6 (3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Respiratory</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9 (4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="Underline">Vision</span></span></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2 (1)</p></td>
</tr>
</tbody>
</table>
<p>Other adverse events that were reported at an incidence of &lt; 1% in the overall clinical studies follow:</p>
<p><span class="Bold">Body as a Whole: </span>facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span></p>
<p><span class="Bold">Cardiovascular System: </span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span></p>
<p><span class="Bold">Digestive System: </span><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span></p>
<p><span class="Bold">Metabolic and Nutritional System: </span><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></p>
<p><span class="Bold">Nervous System: </span><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></p>
<p><span class="Bold">Respiratory System: </span><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span></p>
<p><span class="Bold">Skin and Appendages: </span><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><span class="Bold">Special Senses: </span><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span></p>
<p><span class="Bold">Urogenital System: </span><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">increased libido</span></p>
<p> The safety of cabergoline has been evaluated in approximately 1,200 patients with Parkinson’s disease in controlled and uncontrolled studies at dosages of up to 11.5 mg/day which greatly exceeds the maximum recommended dosage of cabergoline for hyperprolactinemic disorders. In addition to the adverse events that occurred in the patients with hyperprolactinemic disorders, the most common adverse events in patients with Parkinson’s disease were <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>, and gastric or <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span> occurred rarely. One case of <span class="product-label-link" type="condition" conceptid="312334" conceptname="Constrictive pericarditis">constrictive pericarditis</span> has been reported.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b1b05f3-caab-46ab-811d-75477f40f58c"></a><a name="section-7.1"></a><p></p>
<h2>Post-Marketing Surveillance Data</h2>
<p class="First">The following events have been reported in association with cabergoline: <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">cardiac valvulopathy</span> and extracardiac fibrotic reactions (see <a href="#i4i_section_id_775a3e90-bec4-4b32-874c-5f087afdf495">WARNINGS: <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Cardiac Valvulopathy</span></a> and <a href="#i4i_section_id_b200c0f6-ba3a-4398-a075-56adb3fea275">WARNINGS: Extracardiac Fibrotic Reactions</a>).</p>
<p>Others events have been reported in association with cabergoline: <span class="product-label-link" type="condition" conceptid="4032473" conceptname="Nymphomania">hypersexuality</span>, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">increased libido</span>, <span class="product-label-link" type="condition" conceptid="436959" conceptname="Compulsive gambling">pathological gambling</span> (see <a href="#i4i_section_id_4f68ef1b-8e37-45b4-b92b-5411681ed022">PRECAUTIONS: Psychiatric</a>). In addition, cases of <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span> and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic disorder</span> have been reported in patients taking cabergoline. Some of these reports have been in patients who have had prior adverse reactions to dopamine agonist products.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_d4783fe1-b58d-4f63-886a-ce9b99b4677c"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage might be expected to produce <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. Measures to support blood pressure should be taken if necessary.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_b0d6965a-12ae-4392-856b-a40c7b5e0b7f"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dosage of cabergoline tablets for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level. Before initiating treatment, cardiovascular evaluation should be performed and echocardiography should be considered to assess for valvular disease.</p>
<p> Dosage increases should not occur more rapidly than every 4 weeks, so that the physician can assess the patient's response to each dosage level. If the patient does not respond adequately, and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered. Patients receiving long-term treatment with cabergoline should undergo periodic assessment of their cardiac status and echocardiography should be considered.</p>
<p> After a normal serum prolactin level has been maintained for 6 months, cabergoline may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with cabergoline should be reinstituted. The durability of efficacy beyond 24 months of therapy with cabergoline has not been established.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_9112cb94-c653-4b27-a391-f1974d4aeca3"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Cabergoline Tablets, USP are available containing 0.5 mg of cabergoline, USP. </p>
<p> The 0.5 mg tablets are white to off-white, oval, scored tablets debossed with <span class="Bold">M</span> on one side of the tablet and <span class="Bold">C</span> on the left of the score and <span class="Bold">G</span> on the right of the score on the other side. They are available as follows:</p>
<p>NDC 0378-2800-26<br>bottles of 8 tablets</p>
<p>NDC 0378-2800-93<br>bottles of 30 tablets</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505 U.S.A.</p>
<p>OCTOBER 2011<br>CABE:R1</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_11c97f28-455e-42c1-a7c4-293b5a3fbcaa"></a><a name="section-11"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 0.5 mg</span></p>
<p><span class="Bold">NDC 0378-2800-26</span></p>
<p><span class="Bold">Cabergoline</span><br><span class="Bold">Tablets, USP</span></p>
<p><span class="Bold">0.5 mg</span></p>
<p><span class="Bold">Rx only     8 Tablets</span></p>
<p>Each tablet contains:<br>Cabergoline, USP           0.5 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Usual Dosage: </span>See accompanying<br>prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM2800CF1</span></p>
<div class="Figure">
<a name="id1078"></a><img alt="Cabergoline Tablets, USP 0.5 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0e2a2cb6-e453-4060-95f4-a8ce4ccecc10&amp;name=e068ef51-a8cb-428a-9ab0-89d482ad7527-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CABERGOLINE 		
					</strong><br><span class="contentTableReg">cabergoline tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-2800</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CABERGOLINE</strong> (CABERGOLINE) </td>
<td class="formItem">CABERGOLINE</td>
<td class="formItem">0.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LEUCINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;C;G</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-2800-26</td>
<td class="formItem">8  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202947</td>
<td class="formItem">12/02/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e068ef51-a8cb-428a-9ab0-89d482ad7527</div>
<div>Set id: 0e2a2cb6-e453-4060-95f4-a8ce4ccecc10</div>
<div>Version: 3</div>
<div>Effective Time: 20111001</div>
</div>
</div> <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
